Crispr Therapeutics shares tumble after significant earnings miss
LONDON - Hargreave Hale AIM VCT PLC (LON:HHV) has allotted 541,800 new ordinary shares at 36.49 pence per share, raising approximately £198,000, according to a press release issued Friday.
The allotment is part of the company’s offer for subscription announced in October 2024 to raise up to £20 million. The shares were priced based on the net asset value per share as of July 25, 2025, divided by 0.965 to account for offer costs.
The newly issued shares will be admitted to trading on the London Stock Exchange (LON:LSEG)’s main market for listed securities around August 5, 2025. Once issued, they will rank equally with existing ordinary shares.
Following the allotment, the total number of ordinary shares in issue will increase to 372,927,187, with each share carrying one voting right.
The new shares will be issued in registered form and may be held in uncertificated form, with definitive documents of title expected to be dispatched within 15 business days of allotment. The shares will be eligible for settlement through CREST upon admission.
The share issuance was made under the terms outlined in the company’s prospectus published on October 9, 2024, and the supplementary prospectus from December 20, 2024.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.